NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.

Slides:



Advertisements
Similar presentations
THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.
Advertisements

The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.
WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Missing formulations for paediatric HIV treatment and the Dakar Call for Action Improving Access to Optimized Treatment for Children Living with HIV Melbourne,
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
The Role of the IATT Optimal Paediatric ARV Formulary and Considerations for New Product Introduction Nandita Sugandhi, M.D. Clinton Health Access Initiative.
Access to ARVs in low and middle income countries - Joseph Perriëns Coordinator HIV technology and commodities HIV dept. World Health Organization.
Medicines Patent Pool – Strictly Confidential, Not for Circulation Licensing Technology and Intellectual Property for the Development of Paediatric Formulations.
Antiretrovirals Pricing: The Past, The Present, The Future Janice Lee.
Excellent healthcare – locally delivered OVERVIEW OF CLINICAL RECOMMENDATIONS FOR ADULTS, PREGNANT WOMEN AND CHILDREN OVERVIEW OF CLINICAL RECOMMENDATIONS.
Procuring High Quality ARVs at Internationally competitive Prices.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
UNAIDS Strategic Direction 2 Treatment 2.0 Catalysing the next phase of treatment, care & support.
1 |1 | Treatment 2.0 Catalyzing the Next Phase of Scale-up Gottfried Hirnschall Director, HIV Department WHO, Geneva.
WHO-HIV Department Strategic Information Unit AIDS Medicines and Diagnostics Service Contribution to Access to medicines Technical Briefing Seminar, November.
Integrating ART/PMTCT services into MNCH services to enhance test & treat strategy for HIV infected pregnant and lactating women (Option B+) WHO Satellite.
WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.
Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Agenda Introduction- Jessica Rodrigues, IATT Paediatric Treatment Optimization- George Silberry, Senior Technical Advisor for Pediatric HIV, OGAC Optimal.
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Page 0 UNITAID  Melbourne, Australia 2014 Overview of paediatric antiretroviral market : is market in shape to enable achieving targets? Carmen Pérez.
LFA PSM expert workshop January 2014 Strategies for supporting the rational scale-up of laboratory monitoring of HIV.
Optimizing the Paediatric ARV Pipeline Nandita Sugandhi Clinton Health Access Initiative &IATT CSWG ICASA 2015, Harare Zimbabwe November 30, 2015.
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama at Birmingham Birmingham, Alabama Cases From the Clinic(ians):
UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.
ICASA |1 | LEARNING FROM “B+” IMPLICATIONS FOR IMPLEMENTING “TREAT ALL” Dr. Gottfried Hirnschall WHO, Geneva ICASA Harare, December 2015.
The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)
Clinical significance and challenges for transition to new ARVs
MSF Access to Essential Medicines Campaign
WHO perspectives on dolutegravir
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
Characterizing the South Africa ART Market
MPP LICENCES AND OPPORTUNITIES FOR INTRODUCTION OF NEW PRODUCTS AND FORMULATIONS Esteban Burrone, July 2017.
Accelerating access for optimized regimens
Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109
Wits Reproductive Health & HIV Research Institute (RHI)
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
New/Optimal ARV Treatments Why ? & How
HIV-associated TB mortality and blocks in the cascade
The role of Dolutegravir in first-line regimens
Closing the Treatment Gap of Children Living with HIV
Prof. Elaine Abrams September 13th 2018 ICAP at Columbia University
Martina Penazzato MD, PhD Paediatric lead, HIV Department
Optimising ART sub-Saharan Africa
Martina Penazzato (WHO) and Paul L. Domanico (CHAI)
World Health Organization
Marco Vitoria HIV Department Geneva
New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs)  HIV positive.
No Conflict of Interest
Monday, 23 July, 10:15-12:15 Hall 11B, RAI Amsterdam
Dual Antiretroviral Therapy
Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on early infant diagnosis Martina Penazzato MD, PhD Paediatric.
What Will It Take To End Pediatric AIDS
Country Experiences monitoring new ARVs: Introductory Remarks
Overview of the AMDS Products
Meg Doherty MD MPH PhD 24 July 2018 WHO HQ
Thokozani Kalua MBBS MSc Malawi Ministry of Health
Is it Time for a Paradigm Change in HIV Management?
AMDS Products, events and issues.
Toolkit for research and development of paediatric antiretroviral drugs and formulations In collaboration with experts from the Paediatric Antiretroviral.
Adele Schwartz Benzaken
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
How it was possible to offer Integrase Inhibitor as first line ART while maintaining the sustainability of the Brazilian policy of universal access to.
Update From Seattle 2017.
Demand Forecasts for for HIV/AIDS ARV formulations
ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.
Dolutegravir in PEPFAR
Presentation transcript:

NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva

Ensuring the best treatments within a public health approach Optimizing of what we have Ensuring access Looking ahead

Ensuring the best treatments within a public health approach Optimizing of what we have Ensuring access Preparing for the future

Optimizing ART for adults: Conference on Drug Optimization Crawford et al, Lancet ID 2012 Ford et al, Current Opinions 2013 Vitoria et al, JIAS [in press] Improved API synthesis 3TC vs FTC EFV in pregnancy TDF+XTC+EFV remain WHO first choice Dose optimizationPotential of Dolutegravir DTG + EFV 400 mg Long acting formulations Improved formulations of LPV/r for children TDF vs TAF Dual therapy

PHTI-Paediatric Treatment Initiative

Commitment to Action: Stakeholders contribution to 6 core objectives Objective Main Participating Organizations Accelerate the development of high priority pediatric ART formulations PHTI, WHO, originator and generic drug manufacturers Support rapid and streamlined regulatory approval for pediatric ARVs FDA, WHO Ensure that new formulations are promptly eligible for procurement PAPWG, Global Fund Ensure demand forecasts and market sizing data on priority products WHO, UNAIDS, CHAI Track financing commitments for procurement of pediatric ARVs PEPFAR, Global Fund, UNITAID, PAPWG Support demand creation and uptake of pediatric ART formulations CHAI, IATT, PEPFAR

Ensuring access: price variations for ART Lowest price (U$)Highest Price (U$)Median Price (U$) TDF/FTC/EFV TDF/3TC/EFV AZT/3TC/NVP LPV/r ATV/r RAL DRV AMDS, 2015

Integrase inhibitors for 1 st & 2 nd line DTG and TAF for children Induction/maintenance Long acting agents Strategies or regimen for stable patients Preparing for the future

LATTE STUDY: VIROLOGIC SUCCESS DURING INDUCTION AND MAINTENANCE PHASES

Acknowledgements Marco Vitoria Meg Doherty Vincent Habiyambere Ed Mills Steve Kanters Martina Penazzato

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.